Lumos Pharma initiates Phase 2b pediatric growth hormone deficiency study

Lumos Pharma (NASDAQ:LUMO) launched a Phase 2b trial evaluating LUM-201 for the treatment of pediatric growth hormone deficiency (PGHD).

PGHD is typically caused by the pituitary gland’s inability to make sufficient amounts growth hormone. LUM-201 is an oral growth hormone secretagogue that has received orphan drug designations in both the U.S. and EU.

The trial will evaluate three dose levels of LUM-201 in PGHD patients, compared with  standard-of-care injectable growth hormone therapy, over a period of six months. The study’s primary outcome measure is annualized growth height. 

The company expects data from the trial in mid-2022.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.